cas 31181-90-5|| where to buy 5-bromopyridine-2-carbaldehyde

Nom du produit:5-bromopyridine-2-carbaldehyde

IUPAC Name:5-bromopyridine-2-carbaldehyde

Unité d'emballage	Stock disponible	Prix($)
CM104127-25g	in stock	Ȍſ
CM104127-100g	in stock	ƱȌƙ
CM104127-500g	1-2 Weeks	ƻƻǕƻ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 31181-90-5 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:31181-90-5; Formule moléculaire:C6H4BrNO; Point de fusion:-; Code SMILES:[H]C(=O)C1=NC=C(Br)C=C1; Densité:

: Numéro de catalogue:CM104127; Poids moléculaire:186.01; Point d'ébullition:237.7°C at 760 mmHg; N° Mdl:MFCD04112535; Stockage:Keep in Inert atmosphere, store at 2-8°C.

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Camizestrant; Recently, Evaluate Pharma released an analysis report on the trends in the biopharmaceutical industry in 2024. The report mentioned 10 potential key R&D pipelines, including the small molecule drug camizestrant. Camizestrant is a next-generation oral SERD and pure Erα antagonist that has demonstrated anti-cancer activity across a range of preclinical models, including in patients with ER-activating mutations.